Voyager Therapeutics corrects Q3 2026 filing header
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Voyager Therapeutics, Inc. reported third-quarter 2026 results; this amendment corrects only the EDGAR submission header to reference Items 2.02 and 9.01, leaving the original disclosures unchanged. Collaboration revenue was $4.014 million, down from $13.365 million in Q3 2025. Net loss narrowed to $24.694 million from $27.892 million in Q3 2025, while total operating expenses were $30.436 million, compared with $43.959 million in Q3 2025. Excluding reimbursed research and development services, non-GAAP net collaboration revenue was $612,000, compared with $11.153 million a year earlier.
Voyager ended September 30, 2026 with $132.133 million in cash, cash equivalents and marketable securities and said its cash runway extends into Q2 2028. The company expects to report PET imaging data from VY7523 in Q4 2026; VY1706 dosing is expected in the next few months, pending enrollment. Its Neurocrine-partnered Friedreich’s ataxia gene therapy program is expected to enter the clinic in the coming months.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQuarterly net loss narrowed to $24.694 million, from $27.892 million in Q3 2025.
Negative
- Moderate pointQuarterly collaboration revenue fell to $4.014 million, from $13.365 million in Q3 2025.
8-K Event Classification
Key Figures
Key Terms
net collaboration revenue financial
reimbursable research and development services financial
TRACER™ AAV capsid discovery platform technical
multiple ascending dose trial medical
PET imaging data medical
cash runway financial
Earnings Snapshot
Voyager expects VY7523 PET imaging data in Q4 2026. VY1706 dosing is expected in the next few months, pending enrollment. The Neurocrine-partnered Friedreich’s ataxia gene therapy program is expected to enter the clinic in the coming months.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were VYGR’s third-quarter 2026 financial results?
How much cash did VYGR report at the end of Q3 2026?
How does VYGR define non-GAAP net collaboration revenue?
AI-generated analysis. How Rhea-AI works. Not financial advice.